PubMed=1375928; DOI=10.1007/BF02877054
Hellmen E.
Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines.
In Vitro Cell. Dev. Biol. Anim. 28:309-319(1992)

PubMed=9042250
van Leeuwen I.S., Hellmen E., Cornelisse C.J., van der Burg B., Rutteman G.R.
p53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Anticancer Res. 16:3737-3744(1996)

PubMed=19609018
Krol M., Pawlowski K.M., Skierski J.S., Rao N.A.S., Hellmen E., Mol J.A., Motyl T.
Transcriptomic profile of two canine mammary cancer cell lines with different proliferative and anti-apoptotic potential.
J. Physiol. Pharmacol. 60 Suppl. 1:95-106(2009)

PubMed=20453304; DOI=10.1007/BF03195725
Krol M., Pawlowski K.M., Skierski J.S., Turowski P., Majewska A., Polanska J., Ugorski M., Morty R.E., Motyl T.
Transcriptomic 'portraits' of canine mammary cancer cell lines with various phenotypes.
J. Appl. Genet. 51:169-183(2010)

PubMed=22235976; DOI=10.1111/j.1476-5829.2011.00269.x
Pawlowski K.M., Popielarz D.T., Szyszko K., Gajewska M., Motyl T., Krol M.
Growth hormone receptor (GHR) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell line.
Vet. Comp. Oncol. 10:2-15(2012)